<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=930&amp;modal=1&amp;valnames=exclusion_criteria&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="494807" class="table-">
                
                <td>June 25, 2024, noon</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria">
            * patients with indication for full anticoagulation during inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve prosthesis);
* platelets \&lt; 50,000 /mm3
* need for asa therapy \&gt; 100 mg;
* need for p2y12 inhibitor therapy (clopidogrel, ticagrelor or prasugrel);
* chronic use of non-hormonal anti-inflammatory drugs;
* sustained uncontrolled systolic blood pressure (bp) of ≥180 mmhg or diastolic bp of ≥100 mmhg;
* inr \&gt; 1,5;
* patients contraindicated to full anticoagulation (active bleeding, liver failure, blood dyscrasia or prohibitive hemorrhage risk as evaluated by the investigator);
* criteria for disseminated intravascular coagulation (dic);
* a history of hemorrhagic stroke or any intracranial bleeding at any time in the past or current intracranial neoplasm (benign or malignant), cerebral metastases, arteriovenous (av) malformation, or aneurysm;
* active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission or requiring active chemotherapy or adjunctive therapies such as immunotherapy or radiotherapy;
* hypersensitivity to rivaroxaban;
* use of strong inhibitors of cytochrome p450 (cyp) 3a4 and/or p-glycoprotein (p-gp) (e.g. protease inhibitors, ketoconazole, itraconazole) and/or use of p-gp and strong cyp3a4 inducers (such as but not limited to rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or st. john&#x27;s wort);
* known hiv infection;
* creatinine clearance \&lt; 30 ml/min according to the cockcroft-gault formula;
* pregnancy or breastfeeding.
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria validated">
            * patients with indication for full anticoagulation during inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve prosthesis);
* platelets \&lt; 50,000 /mm3
* need for asa therapy \&gt; 100 mg;
* need for p2y12 inhibitor therapy (clopidogrel, ticagrelor or prasugrel);
* chronic use of non-hormonal anti-inflammatory drugs;
* sustained uncontrolled systolic blood pressure (bp) of ≥180 mmhg or diastolic bp of ≥100 mmhg;
* inr \&gt; 1,5;
* patients contraindicated to full anticoagulation (active bleeding, liver failure, blood dyscrasia or prohibitive hemorrhage risk as evaluated by the investigator);
* criteria for disseminated intravascular coagulation (dic);
* a history of hemorrhagic stroke or any intracranial bleeding at any time in the past or current intracranial neoplasm (benign or malignant), cerebral metastases, arteriovenous (av) malformation, or aneurysm;
* active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission or requiring active chemotherapy or adjunctive therapies such as immunotherapy or radiotherapy;
* hypersensitivity to rivaroxaban;
* use of strong inhibitors of cytochrome p450 (cyp) 3a4 and/or p-glycoprotein (p-gp) (e.g. protease inhibitors, ketoconazole, itraconazole) and/or use of p-gp and strong cyp3a4 inducers (such as but not limited to rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or st. john&#x27;s wort);
* known hiv infection;
* creatinine clearance \&lt; 30 ml/min according to the cockcroft-gault formula;
* pregnancy or breastfeeding.
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="29745" class="table-">
                
                <td>Oct. 26, 2020, 11:31 p.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria">
            -  patients with indication for full anticoagulation during inclusion (for example,
             diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve
             prosthesis);

          -  platelets &lt; 50,000 /mm3

          -  need for asa therapy &gt; 100 mg;

          -  need for p2y12 inhibitor therapy (clopidogrel, ticagrelor or prasugrel);

          -  chronic use of non-hormonal anti-inflammatory drugs;

          -  sustained uncontrolled systolic blood pressure (bp) of ≥180 mmhg or diastolic bp of
             ≥100 mmhg;

          -  inr &gt; 1,5;

          -  patients contraindicated to full anticoagulation (active bleeding, liver failure,
             blood dyscrasia or prohibitive hemorrhage risk as evaluated by the investigator);

          -  criteria for disseminated intravascular coagulation (dic);

          -  a history of hemorrhagic stroke or any intracranial bleeding at any time in the past
             or current intracranial neoplasm (benign or malignant), cerebral metastases,
             arteriovenous (av) malformation, or aneurysm;

          -  active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission
             or requiring active chemotherapy or adjunctive therapies such as immunotherapy or
             radiotherapy;

          -  hypersensitivity to rivaroxaban;

          -  use of strong inhibitors of cytochrome p450 (cyp) 3a4 and/or p-glycoprotein (p-gp)
             (e.g. protease inhibitors, ketoconazole, itraconazole) and/or use of p-gp and strong
             cyp3a4 inducers (such as but not limited to rifampin/rifampicin, rifabutin,
             rifapentine, phenytoin, phenobarbital, carbamazepine, or st. john&#x27;s wort);

          -  known hiv infection;

          -  creatinine clearance &lt; 30 ml/min according to the cockcroft-gault formula;

          -  pregnancy or breastfeeding.
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria validated">
            -  patients with indication for full anticoagulation during inclusion (for example,
             diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve
             prosthesis);

          -  platelets &lt; 50,000 /mm3

          -  need for asa therapy &gt; 100 mg;

          -  need for p2y12 inhibitor therapy (clopidogrel, ticagrelor or prasugrel);

          -  chronic use of non-hormonal anti-inflammatory drugs;

          -  sustained uncontrolled systolic blood pressure (bp) of ≥180 mmhg or diastolic bp of
             ≥100 mmhg;

          -  inr &gt; 1,5;

          -  patients contraindicated to full anticoagulation (active bleeding, liver failure,
             blood dyscrasia or prohibitive hemorrhage risk as evaluated by the investigator);

          -  criteria for disseminated intravascular coagulation (dic);

          -  a history of hemorrhagic stroke or any intracranial bleeding at any time in the past
             or current intracranial neoplasm (benign or malignant), cerebral metastases,
             arteriovenous (av) malformation, or aneurysm;

          -  active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission
             or requiring active chemotherapy or adjunctive therapies such as immunotherapy or
             radiotherapy;

          -  hypersensitivity to rivaroxaban;

          -  use of strong inhibitors of cytochrome p450 (cyp) 3a4 and/or p-glycoprotein (p-gp)
             (e.g. protease inhibitors, ketoconazole, itraconazole) and/or use of p-gp and strong
             cyp3a4 inducers (such as but not limited to rifampin/rifampicin, rifabutin,
             rifapentine, phenytoin, phenobarbital, carbamazepine, or st. john&#x27;s wort);

          -  known hiv infection;

          -  creatinine clearance &lt; 30 ml/min according to the cockcroft-gault formula;

          -  pregnancy or breastfeeding.
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
June 25, 2024, noon	usa	* patients with indication for full anticoagulation during inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve prosthesis); * platelets \< 50,000 /mm3 * need for asa therapy \> 100 mg; * need for p2y12 inhibitor therapy (clopidogrel, ticagrelor or prasugrel); * chronic use of non-hormonal anti-inflammatory drugs; * sustained uncontrolled systolic blood pressure (bp) of ≥180 mmhg or diastolic bp of ≥100 mmhg; * inr \> 1,5; * patients contraindicated to full anticoagulation (active bleeding, liver failure, blood dyscrasia or prohibitive hemorrhage risk as evaluated by the investigator); * criteria for disseminated intravascular coagulation (dic); * a history of hemorrhagic stroke or any intracranial bleeding at any time in the past or current intracranial neoplasm (benign or malignant), cerebral metastases, arteriovenous (av) malformation, or aneurysm; * active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission or requiring active chemotherapy or adjunctive therapies such as immunotherapy or radiotherapy; * hypersensitivity to rivaroxaban; * use of strong inhibitors of cytochrome p450 (cyp) 3a4 and/or p-glycoprotein (p-gp) (e.g. protease inhibitors, ketoconazole, itraconazole) and/or use of p-gp and strong cyp3a4 inducers (such as but not limited to rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or st. john's wort); * known hiv infection; * creatinine clearance \< 30 ml/min according to the cockcroft-gault formula; * pregnancy or breastfeeding.	* patients with indication for full anticoagulation during inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve prosthesis); * platelets \< 50,000 /mm3 * need for asa therapy \> 100 mg; * need for p2y12 inhibitor therapy (clopidogrel, ticagrelor or prasugrel); * chronic use of non-hormonal anti-inflammatory drugs; * sustained uncontrolled systolic blood pressure (bp) of ≥180 mmhg or diastolic bp of ≥100 mmhg; * inr \> 1,5; * patients contraindicated to full anticoagulation (active bleeding, liver failure, blood dyscrasia or prohibitive hemorrhage risk as evaluated by the investigator); * criteria for disseminated intravascular coagulation (dic); * a history of hemorrhagic stroke or any intracranial bleeding at any time in the past or current intracranial neoplasm (benign or malignant), cerebral metastases, arteriovenous (av) malformation, or aneurysm; * active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission or requiring active chemotherapy or adjunctive therapies such as immunotherapy or radiotherapy; * hypersensitivity to rivaroxaban; * use of strong inhibitors of cytochrome p450 (cyp) 3a4 and/or p-glycoprotein (p-gp) (e.g. protease inhibitors, ketoconazole, itraconazole) and/or use of p-gp and strong cyp3a4 inducers (such as but not limited to rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or st. john's wort); * known hiv infection; * creatinine clearance \< 30 ml/min according to the cockcroft-gault formula; * pregnancy or breastfeeding.
Oct. 26, 2020, 11:31 p.m.	usa	- patients with indication for full anticoagulation during inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve prosthesis); - platelets < 50,000 /mm3 - need for asa therapy > 100 mg; - need for p2y12 inhibitor therapy (clopidogrel, ticagrelor or prasugrel); - chronic use of non-hormonal anti-inflammatory drugs; - sustained uncontrolled systolic blood pressure (bp) of ≥180 mmhg or diastolic bp of ≥100 mmhg; - inr > 1,5; - patients contraindicated to full anticoagulation (active bleeding, liver failure, blood dyscrasia or prohibitive hemorrhage risk as evaluated by the investigator); - criteria for disseminated intravascular coagulation (dic); - a history of hemorrhagic stroke or any intracranial bleeding at any time in the past or current intracranial neoplasm (benign or malignant), cerebral metastases, arteriovenous (av) malformation, or aneurysm; - active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission or requiring active chemotherapy or adjunctive therapies such as immunotherapy or radiotherapy; - hypersensitivity to rivaroxaban; - use of strong inhibitors of cytochrome p450 (cyp) 3a4 and/or p-glycoprotein (p-gp) (e.g. protease inhibitors, ketoconazole, itraconazole) and/or use of p-gp and strong cyp3a4 inducers (such as but not limited to rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or st. john's wort); - known hiv infection; - creatinine clearance < 30 ml/min according to the cockcroft-gault formula; - pregnancy or breastfeeding.	- patients with indication for full anticoagulation during inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve prosthesis); - platelets < 50,000 /mm3 - need for asa therapy > 100 mg; - need for p2y12 inhibitor therapy (clopidogrel, ticagrelor or prasugrel); - chronic use of non-hormonal anti-inflammatory drugs; - sustained uncontrolled systolic blood pressure (bp) of ≥180 mmhg or diastolic bp of ≥100 mmhg; - inr > 1,5; - patients contraindicated to full anticoagulation (active bleeding, liver failure, blood dyscrasia or prohibitive hemorrhage risk as evaluated by the investigator); - criteria for disseminated intravascular coagulation (dic); - a history of hemorrhagic stroke or any intracranial bleeding at any time in the past or current intracranial neoplasm (benign or malignant), cerebral metastases, arteriovenous (av) malformation, or aneurysm; - active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission or requiring active chemotherapy or adjunctive therapies such as immunotherapy or radiotherapy; - hypersensitivity to rivaroxaban; - use of strong inhibitors of cytochrome p450 (cyp) 3a4 and/or p-glycoprotein (p-gp) (e.g. protease inhibitors, ketoconazole, itraconazole) and/or use of p-gp and strong cyp3a4 inducers (such as but not limited to rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or st. john's wort); - known hiv infection; - creatinine clearance < 30 ml/min according to the cockcroft-gault formula; - pregnancy or breastfeeding.